Redx Pharma PLC (LON:REDX) said its second fibrosis drug candidate will enter the clinic in the first half of next year.
RXC007 has been designed to target ROCK2, a nodal enzyme in cell signalling pathways associated with idiopathic pulmonary fibrosis (IPF), a chronic lung condition with a poor prognosis.
It may also serve as a treatment for a liver disease called non-alcoholic steatohepatitis and a severe kidney problem called diabetic nephropathy.
Early indications from the company’s ROCK2 programme suggest the drug has “robust anti-fibrotic effects” and that it can be taken orally. Additionally, it is expected to have a safe cardiovascular profile.
This is the second cab off the rank in the field of fibrosis for Redx. It is also developing RXC006, which is intended to be the first drug in this class for IPF.
"Redx is pleased to be progressing the development of this exciting drug candidate that selectively inhibits ROCK2 as a potential treatment for multiple fibrotic diseases,” said chief executive Lisa Anson.
“This is a challenging area of chemistry and the Redx team is proud to deliver another successful drug candidate.”